Mitochondrial disorders

Current Opinion in Neurology

Volumn 10, Issue 1, 1997, Pages 43-47

  Schapira, A H V ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA;

APOPTOSIS; CALCIUM HOMEOSTASIS; CELL DEATH; CELL FUNCTION; CELL NUCLEUS; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY RESOURCE; ETIOLOGY; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; PARKINSON DISEASE; RESPIRATORY CHAIN; REVIEW;

EID: 0030897310     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199702000-00009     Document Type: Review

References (31)

1. Moraes CT: Mitochondrial disorders. Curr Opin Neurol 1996, 9:369-374.
2. Schapira AHV: Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr Opin Neurol 1996, 9:260-264.
3. Howell N, Kubacka I, Mackey DA: How rapidly does the human mitochondrial genome evolve? Am J Hum Genet 1996, 59:501-509. D-loop sequencing individuals in a LHON pedigree documented the appearance of new mutations and plotted segregation through the lineage. This paper is important in causing us to re-evaluate the evolutionary rate of mtDNA and the assumption that heteroplasmy is synonymous with pathogenicity.
4. Pääbo S: Mutational hot spots in the mitochondrial microcosm. Am J Hum Genet 1996, 59:493-496.
5. Chen X, Prosser R, Simonetti S, Sadlock J, Jagiello G, Schon EA: Rearranged mitochondrial genomes are present in human oocytes. Am J Hum Genet 1995, 57:239-247. mtDNA molecules bearing the common deletion are present in control oocytes. This observation helps understanding of the origin of sporadic mitochondrial disorders such as Kearns-Sayre syndrome and chronic progressive external opthalmoplegia.
6. Dunbar DR, Moonie PA, Zeviani M, Holt IJ: Complex I deficiency is associated with 3243G:C mitochondrial DNA in osteosarcoma cell cybrids. Hum Mol Genet 1996, 5:123-129. See [7•].
7. Kaufmann P, Koga Y, Shanske S, Hirano M, DiMauro S, King MP, Schon EA: Mitochondrial DNA and RNA processing in MELAS. Ann Neurol 1996, 40:172-180. The 3243 mutation caused a significant complex I deficiency at a lower mutation threshold than previously observed. This mutation may cause impaired protein translation through an RNA-19 transcript blockade of mitochondrial ribosomes.
8. Leu(UUR) mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Mol Cell Biol 1992, 12:480-490.
9. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC: Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993, 361:365-369.
10. Jacobson MD, Burne JF, Raff MC: Programmed cell death and Bcl-2 protection in the absence of a nucleus. Eur Mol Biol Organ J 1994, 13:1899-1910.
11. Newmeyer DD, Farshcon DM, Reed JC: Cell-free apoptosis in Xenopus egg extracts: inhibition of Bcl-2 and requirements for an organelle fraction enriched in mitochondria. Cell 1994, 79:353-364.
12. Marchetti P, Susin SA, Decaudin D, Gamen S, Castedo M, Hirsch T, Zamzami N, Naval J, Senik A, Kroemer G: Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res 1996, 56:2033-2018. Changes in mitochondrial transmembrane potential precede the generation of reactive oxygen species and DNA fragmentation. A mitochondrial factor greater than 10 000 Da is released during transmembrane potential induced mega-channel opening and is important in the apoptotic process.
13. Bodnar AG, Cooper JM, Leonard JV, Schapira AHV: Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication. Biochem J 1995, 305:817-822.
14. Bernardi P, Broeckemeier KM, Pfieffer DR: Recent progress on regulation of the mitochondrial permeability transition pore: a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerg Biomembr 1994, 26:509-517.
15. Fadok VA, Voleker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure to phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992, 148:2207-2216.
16. Castedo M, Hirsch T, Susin SA, Zamzami N, Marchetti P, Macho A, Kroemer G: Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosls. J Immunol 1996, 157:512-521.
17. Harding AE, Sweeney MG, Govan GG, Riordan-Eva P: Pedigree analysis in Leber's hereditary optic neuropathy families with a pathogenic mtDNA mutation. Am J Hum Genet 1995, 57:77-86. A detailed analysis of UK LHON pedigrees which described penetration and recurrence risks in family members. A potential role for the X chromosome in determining susceptibility is supported but not confirmed.
18. Chalmers RM, Davis MB, Sweeney MG, Wood NW, Harding AE: Evidence against an X-linked visual loss susceptibility locus in Leber's hereditary optic neuropathy. Am J Hum Genet 1996, 59:103-108.
19. Pegoraro E, Carelli V, Zeviani M, Cortelli P, Montagna P, Barboni P, Angelini C, Hoffman EP: X-inactlvatlon patterns in female Leber's hereditary optic neuropathy patients do not support a strong X-linked determinant. Am J Med Genet 1996, 61:356-362.
20. Cock HR, Cooper JM, Schapira AHV: Nuclear complementation in Leber's hereditary optic neuropathy [Abstract]. Neurology 1995, 45:A294.
21. Hofhaus G, Johns DR, Hurko O, Attardi G, Chomyn A: Respiration and growth defects in transmitochondrial cell lines carrying the 11778 mutation associated with Leber's hereditary optic neuropathy. J Biol Chem 1996, 271:13155-13161. The 11778 LHON mutation causes a defect in oxygen utilisation which persists in cybrid cells. This suggests that, at least with this mutation, no nuclear factor is required for biochemical expression.
22. De Vries DD, Went LN, Bruyn GW, Scholte HR, Hofstra RMW, Bolhuis PA, van Ooost BA: Genetic and biochemical impairment of mito-chondrial complex I activity in a family with Leber hereditary optic neuropathy and hereditary spastic dystonia. Am J Hum Genet 1996, 58:703-711. A large LHON-dystonia pedigree with two novel mtDNA mutations.
23. 0 cybrids. The mutation may affect the coenzyme Q binding site of complex I.
24. Benecke R, Strümper P, Weiss H: Electron transfer complex I defect in idiopathic dystonia. Ann Neurol 1992, 32:683-686.
25. Schapira AHV, Warner T, Gash MT, Cleeter MJW, Marinho CFM, Cooper JM: Complex I function in familial and sporadic dystonia. Ann Neurol 1997 (in press).
26. De Rooij KE, Dorsman JC, Smoor MA, Den Dunnam JT, van Ommen GJB: Subcellular localization of Huntington's disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. Hum Mol Genet 1996, 5:1093-1099.
27. Kuwert T, Lange HW, Langer K-J, Herzog H, Aulich A, Feinendegen LE: Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 1990, 113: 1405-1423.
28. Martin WRW, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR: Cortical glucose metabolism in Huntington's disease. Neurology 1992, 42:223-229.
29. 1H NMR spectroscopy. Neurology 1993, 43:2689-2695
30. Koroshetz WJ, Jenkins B, Rosen B, Beal MF: Evidence for a metabolic disorder in Huntington's disease [Abstract]. Neurology 1994, 44:A338.
31. Gu M, Cooper JM, Gash M, Mann VM, Javoy-Agid F, Schapira AHV: Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996, 39:385-389. A severe deficiency of complexes II and III was seen in Huntington's disease caudate nucleus. This supports the existence of a defect of energy metabolism in the pathogenesis of the disease.